董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Stan K. Erickson Director 75 14.43万美元 未持股 2025-11-14
Andrea M. Walsh Director 62 13.93万美元 未持股 2025-11-14
Andrew Summers Director 52 13.63万美元 未持股 2025-11-14
Joseph L. Galatowitsch Director 67 13.43万美元 未持股 2025-11-14
James L. Cunniff President and Chief Executive Officer and Director 60 148.63万美元 未持股 2025-11-14
Gregory J. Fluet Director 56 14.13万美元 未持股 2025-11-14
Kathleen A. Tune Director 61 16.68万美元 未持股 2025-11-14
Kathleen S. Skarvan Director 69 15.88万美元 未持股 2025-11-14

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
James L. Cunniff President and Chief Executive Officer and Director 60 148.63万美元 未持股 2025-11-14
Bradley M. Nagel Chief Financial Officer, Treasurer and Secretary 43 75.67万美元 未持股 2025-11-14

董事简历

中英对照 |  中文 |  英文
Stan K. Erickson

Stan K. Erickson,2014年11月在股东2014财年年度会议上被第一个选到董事会。他目前是一家他于2013年9月联合创立的、提供资本和咨询服务的公司- Liberty Capital, Inc.的总裁和首席执行官。2012年11月,他从供职了32年的ZieglerCat, Inc.退休,该公司是美国最大的Caterpillar经销商之一,他最近担任该公司的总裁和首席运营官。他是United States Marine Corps的一位老将,持有Minnesota大学的商务学位、注册会计师协会证;是从担任审计员和税务专家开始他的商业职业生涯的。他曾积极参与数个私有企业的董事会、咨询委员会和协会。


Stan K. Erickson,provides a strong perspective on financing, investment, acquisition and operating strategies, public company regulatory compliance issues, and investor relations. Mr. Erickson currently serves as President and Chief Executive Officer of Liberty Capital, Inc., which he co-founded in 2013 to provide capital and advisory services to both pre- and post-commercialization organizations in various industries, including medical device and technology.BS, Business Administration, University of Minnesota;Certified Public Accountant (Inactive).
Stan K. Erickson,2014年11月在股东2014财年年度会议上被第一个选到董事会。他目前是一家他于2013年9月联合创立的、提供资本和咨询服务的公司- Liberty Capital, Inc.的总裁和首席执行官。2012年11月,他从供职了32年的ZieglerCat, Inc.退休,该公司是美国最大的Caterpillar经销商之一,他最近担任该公司的总裁和首席运营官。他是United States Marine Corps的一位老将,持有Minnesota大学的商务学位、注册会计师协会证;是从担任审计员和税务专家开始他的商业职业生涯的。他曾积极参与数个私有企业的董事会、咨询委员会和协会。
Stan K. Erickson,provides a strong perspective on financing, investment, acquisition and operating strategies, public company regulatory compliance issues, and investor relations. Mr. Erickson currently serves as President and Chief Executive Officer of Liberty Capital, Inc., which he co-founded in 2013 to provide capital and advisory services to both pre- and post-commercialization organizations in various industries, including medical device and technology.BS, Business Administration, University of Minnesota;Certified Public Accountant (Inactive).
Andrea M. Walsh

Andrea M.Walsh目前担任HealthPartners的总裁兼首席执行官,HealthPartners是一家总部位于明尼苏达州,价值75亿美元的非营利性综合医疗系统,提供护理,健康支持,保险范围,研究和教育计划。在HealthPartners的27年职业生涯中,沃尔什女士担任过多个职责递增的职位,包括执行副总裁和首席营销官,从2002年4月至2017年5月,从1994年至1999年担任高级副总裁兼公司法律顾问,负责制定组织的愿景和战略,以在市场上提供最高质量,负担得起的最佳护理和经验。在担任总裁兼首席执行官期间,沃尔什女士管理着一个由26500人组成的团队,其中包括一个多专业集团,拥有1700多名医生和900名高级临床医生,这些医生为明尼苏达州和威斯康星州的120多万患者提供服务,通过其健康计划,网络和服务,在全国拥有180万会员。沃尔什女士自2016年以来一直担任医疗专业责任相互保险公司Constellation的董事会成员,自2019年以来一直担任双城基督教青年会的董事会成员。Walsh女士拥有堪萨斯大学的工商管理和英语学位,以及明尼苏达大学法学院的法学博士学位。


Andrea M. Walsh,currently serves as President and Chief Executive Officer of HealthPartners, an $8.5 billion Minnesota-based non-profit integrated health system that provides care, health support, insurance coverage, research and education programs. She has held this position since 2017. Over her 30-year career with HealthPartners, Ms. Walsh held other positions, including as Executive Vice President and Chief Marketing Officer, from April 2002 to May 2017 and as Senior Vice President and Corporate Counsel from 1994 to 1999. In her role as President and Chief Executive Officer, Ms. Walsh is responsible for developing the organization's vision and strategy. She leads a team of approximately 28,000 people, including a multi-specialty group practice with over 1,800 physicians and 900 advanced practice clinicians, which collectively serve more than 1.3 million patients in Minnesota and Wisconsin, and 1.7 million members across the country through its health plan, network and services.BA, Business Administration & English, University of Kansas;JD, University of Minnesota Law School.
Andrea M.Walsh目前担任HealthPartners的总裁兼首席执行官,HealthPartners是一家总部位于明尼苏达州,价值75亿美元的非营利性综合医疗系统,提供护理,健康支持,保险范围,研究和教育计划。在HealthPartners的27年职业生涯中,沃尔什女士担任过多个职责递增的职位,包括执行副总裁和首席营销官,从2002年4月至2017年5月,从1994年至1999年担任高级副总裁兼公司法律顾问,负责制定组织的愿景和战略,以在市场上提供最高质量,负担得起的最佳护理和经验。在担任总裁兼首席执行官期间,沃尔什女士管理着一个由26500人组成的团队,其中包括一个多专业集团,拥有1700多名医生和900名高级临床医生,这些医生为明尼苏达州和威斯康星州的120多万患者提供服务,通过其健康计划,网络和服务,在全国拥有180万会员。沃尔什女士自2016年以来一直担任医疗专业责任相互保险公司Constellation的董事会成员,自2019年以来一直担任双城基督教青年会的董事会成员。Walsh女士拥有堪萨斯大学的工商管理和英语学位,以及明尼苏达大学法学院的法学博士学位。
Andrea M. Walsh,currently serves as President and Chief Executive Officer of HealthPartners, an $8.5 billion Minnesota-based non-profit integrated health system that provides care, health support, insurance coverage, research and education programs. She has held this position since 2017. Over her 30-year career with HealthPartners, Ms. Walsh held other positions, including as Executive Vice President and Chief Marketing Officer, from April 2002 to May 2017 and as Senior Vice President and Corporate Counsel from 1994 to 1999. In her role as President and Chief Executive Officer, Ms. Walsh is responsible for developing the organization's vision and strategy. She leads a team of approximately 28,000 people, including a multi-specialty group practice with over 1,800 physicians and 900 advanced practice clinicians, which collectively serve more than 1.3 million patients in Minnesota and Wisconsin, and 1.7 million members across the country through its health plan, network and services.BA, Business Administration & English, University of Kansas;JD, University of Minnesota Law School.
Andrew Summers

Andrew Summers,现任Summers Value Partners LLC(“Summers Value Partners”)管理成员,该公司是一家专注于全球医疗保健领域小型和微型公司的另类投资管理公司。萨默斯自2018年3月起担任这一职务。在创立Summers Value Partners之前,Summers先生曾于2008年至2018年2月在领先的全球主动型资产管理公司Janus Henderson集团有限公司(d/b/a Janus Henderson投资公司)担任投资专业人士和股票分析师,专门从事全球医疗保健领域的投资。从2004年到2008年,萨默斯先生担任Silvergate资本管理有限责任公司的管理成员,这是一家由他创立的多/空医疗保健对冲基金。1998年,萨默斯在投资管理公司INVESCO Funds Group,Inc.开始了他的投资生涯,在那里,他最终成为了一只价值35亿美元的医疗保健基金的联合投资组合经理。萨默斯曾于2019年5月至2020年5月担任家庭和个人护理产品公司Scott's Liquid Gold Inc.(OTC:SLGD)的董事。萨默斯在威斯康星大学怀特沃特分校获得工商管理学士学位,在威斯康星大学麦迪逊分校获得金融硕士学位。萨默斯先生是一名特许金融分析师(CFA)。


Andrew Summers,currently serves as the Managing Member of Summers Value Partners LLC ("Summers Value Partners"), an alternative investment management firm with a focus on small and micro-cap companies in the global healthcare sector, since March 2018. Prior to that, Mr. Summers was an investment professional and equity analyst at Janus Henderson Investors, a leading global active asset manager, from 2008 to February 2018, where he specialized in investing across the global healthcare sector. From 2004 to 2008, Mr. Summers served as the Managing Member of Silvergate Capital Management LLC, a long/short healthcare hedge fund that he founded. Mr. Summers began his investment career in 1998 at INVESCO Funds Group, Inc.BS, Business Administration, University of Wisconsin-Whitewater;MS, Finance, University of Wisconsin-Madison;Chartered Financial Analyst.
Andrew Summers,现任Summers Value Partners LLC(“Summers Value Partners”)管理成员,该公司是一家专注于全球医疗保健领域小型和微型公司的另类投资管理公司。萨默斯自2018年3月起担任这一职务。在创立Summers Value Partners之前,Summers先生曾于2008年至2018年2月在领先的全球主动型资产管理公司Janus Henderson集团有限公司(d/b/a Janus Henderson投资公司)担任投资专业人士和股票分析师,专门从事全球医疗保健领域的投资。从2004年到2008年,萨默斯先生担任Silvergate资本管理有限责任公司的管理成员,这是一家由他创立的多/空医疗保健对冲基金。1998年,萨默斯在投资管理公司INVESCO Funds Group,Inc.开始了他的投资生涯,在那里,他最终成为了一只价值35亿美元的医疗保健基金的联合投资组合经理。萨默斯曾于2019年5月至2020年5月担任家庭和个人护理产品公司Scott's Liquid Gold Inc.(OTC:SLGD)的董事。萨默斯在威斯康星大学怀特沃特分校获得工商管理学士学位,在威斯康星大学麦迪逊分校获得金融硕士学位。萨默斯先生是一名特许金融分析师(CFA)。
Andrew Summers,currently serves as the Managing Member of Summers Value Partners LLC ("Summers Value Partners"), an alternative investment management firm with a focus on small and micro-cap companies in the global healthcare sector, since March 2018. Prior to that, Mr. Summers was an investment professional and equity analyst at Janus Henderson Investors, a leading global active asset manager, from 2008 to February 2018, where he specialized in investing across the global healthcare sector. From 2004 to 2008, Mr. Summers served as the Managing Member of Silvergate Capital Management LLC, a long/short healthcare hedge fund that he founded. Mr. Summers began his investment career in 1998 at INVESCO Funds Group, Inc.BS, Business Administration, University of Wisconsin-Whitewater;MS, Finance, University of Wisconsin-Madison;Chartered Financial Analyst.
Joseph L. Galatowitsch

Joseph L. Galatowitsch,最近在Guidehouse Consulting担任合伙人和医疗技术业务负责人,Guidehouse Consulting之前名为Navigant,是一家为公共和商业市场提供咨询服务的全球领先供应商,在管理、技术和风险咨询方面拥有广泛的能力。在加入Guidehouse之前,Galatowitsch先生于2008年1月至2016年8月共同创立并担任Dymedex Consulting,LLC总裁,在那里他开创并提供了新的世界概念框架,用于评估机会并推动临床采用颠覆性的新医疗技术。Galatowitsch先生还在美敦力公司和3M公司担任过越来越重要的职务。在美敦力,他领导并协调了美敦力心律管理部门的全球市场开发工作,为植入式除颤器和心脏起搏器在美国和大多数国际市场的普及做出了巨大贡献。Galatowitsch先生曾于2011年至2021年在Medical Alley(原名LiveScience Alley)董事会任职,该公司是全球健康创新和护理中心,是植入式医疗技术、协作护理提供和创新健康计划模式的诞生地。Galatowitsch先生在马凯特大学获得生物医学工程学士学位,在圣托马斯大学奥普斯商学院获得市场营销MBA学位。


Joseph L. Galatowitsch,most recently served as a Partner and Medtech practice leader at Guidehouse Consulting, a leading global provider of consulting services to the public and commercial markets with broad capabilities in management, technology, and risk consulting. He also co-founded and served as President of Dymedex Consulting, LLC from January 2008 through August 2016 when it was acquired by Navigant up until his retirement in September 2020. He pioneered and provided new-to-the-world conceptual frameworks for assessing opportunities and driving clinical adoption of disruptive new medical technologies. At Medtronic, he led and coordinated global market development efforts in Medtronic's cardiac rhythm management division.BS, Biomedical Engineering, Marquette University;MBA, Marketing, St. Thomas Opus College of Business.
Joseph L. Galatowitsch,最近在Guidehouse Consulting担任合伙人和医疗技术业务负责人,Guidehouse Consulting之前名为Navigant,是一家为公共和商业市场提供咨询服务的全球领先供应商,在管理、技术和风险咨询方面拥有广泛的能力。在加入Guidehouse之前,Galatowitsch先生于2008年1月至2016年8月共同创立并担任Dymedex Consulting,LLC总裁,在那里他开创并提供了新的世界概念框架,用于评估机会并推动临床采用颠覆性的新医疗技术。Galatowitsch先生还在美敦力公司和3M公司担任过越来越重要的职务。在美敦力,他领导并协调了美敦力心律管理部门的全球市场开发工作,为植入式除颤器和心脏起搏器在美国和大多数国际市场的普及做出了巨大贡献。Galatowitsch先生曾于2011年至2021年在Medical Alley(原名LiveScience Alley)董事会任职,该公司是全球健康创新和护理中心,是植入式医疗技术、协作护理提供和创新健康计划模式的诞生地。Galatowitsch先生在马凯特大学获得生物医学工程学士学位,在圣托马斯大学奥普斯商学院获得市场营销MBA学位。
Joseph L. Galatowitsch,most recently served as a Partner and Medtech practice leader at Guidehouse Consulting, a leading global provider of consulting services to the public and commercial markets with broad capabilities in management, technology, and risk consulting. He also co-founded and served as President of Dymedex Consulting, LLC from January 2008 through August 2016 when it was acquired by Navigant up until his retirement in September 2020. He pioneered and provided new-to-the-world conceptual frameworks for assessing opportunities and driving clinical adoption of disruptive new medical technologies. At Medtronic, he led and coordinated global market development efforts in Medtronic's cardiac rhythm management division.BS, Biomedical Engineering, Marquette University;MBA, Marketing, St. Thomas Opus College of Business.
James L. Cunniff

James L. Cunniff,2023年7月加入Electromed,担任公司总裁兼首席执行官。在加入Electromed之前,Cunniff先生最近于2017年至2022年5月担任Provista Inc.的总裁兼首席执行官。此前,他曾于2015年至2017年在Denver Solutions,LLC(d/b/a Leiters Health)担任总裁兼首席执行官,并于2012年至2014年在Acelity L.P. Inc.担任美洲区高级副总裁。Cunniff先生拥有伊利诺伊大学厄巴纳-香槟分校的广告和商业学士学位,并完成了哈佛商学院的高级管理课程。


James L. Cunniff,is a seasoned executive in the healthcare space with a direct knowledge of Electromed's business and operations as he currently serves as President and Chief Executive Officer of Electromed, Inc. Prior to joining Electromed in July of 2023, he served as President and Chief Executive Officer of Provista, Inc. (2017-2022) and of Denver Solutions, LLC (2015-2017).BA, Advertising and Business, University of Illinois Urbana-Champaign;Advanced Management Program, Harvard Business School.
James L. Cunniff,2023年7月加入Electromed,担任公司总裁兼首席执行官。在加入Electromed之前,Cunniff先生最近于2017年至2022年5月担任Provista Inc.的总裁兼首席执行官。此前,他曾于2015年至2017年在Denver Solutions,LLC(d/b/a Leiters Health)担任总裁兼首席执行官,并于2012年至2014年在Acelity L.P. Inc.担任美洲区高级副总裁。Cunniff先生拥有伊利诺伊大学厄巴纳-香槟分校的广告和商业学士学位,并完成了哈佛商学院的高级管理课程。
James L. Cunniff,is a seasoned executive in the healthcare space with a direct knowledge of Electromed's business and operations as he currently serves as President and Chief Executive Officer of Electromed, Inc. Prior to joining Electromed in July of 2023, he served as President and Chief Executive Officer of Provista, Inc. (2017-2022) and of Denver Solutions, LLC (2015-2017).BA, Advertising and Business, University of Illinois Urbana-Champaign;Advanced Management Program, Harvard Business School.
Gregory J. Fluet

GregoryJ.Fluet目前是Ferring制药公司Rebiotix的首席运营官。自2016年11月以来,他一直在Rebiotix工作,担任合同和永久职位,包括从2017年4月起担任首席商务官,直到2018年4月被Ferring Pharmaceuticals收购。此前,他曾从事战略咨询实践,任职初创生命科学公司。他曾于2012年至2016年1月担任Urologix,Inc.(当时为一家上市公司)的首席执行官。他还曾于2014年8月至2015年5月担任其临时首席财务官,并于2008年至2012年担任其执行Vice President兼首席运营官。从2002年到2008年,他曾担任Sapient Capital Management公司(一个专注于梦百合的风险投资基金)的合伙人。他在Stanford University获得机械工程学士学位。


Gregory J. Fluet,serves as Chief Operating Officer for Ferring Microbiome Inc. (fka Rebiotix, Inc.), a Ferring Pharmaceuticals company focused on revolutionizing the treatment of debilitating diseases through microbiome-based research. Since 2016, he has worked at Rebiotix in both contract and permanent roles, including serving as Chief Business Officer from 2017 until the company's acquisition by Ferring Pharmaceuticals in 2018. Prior to this role at Rebiotix, Mr. Fluet served as Chief Executive Officer of Urologix, Inc., then a public company and developer of minimally invasive office-based Benign Prostatic Hyperplasia (BPH) therapies.BS, Mechanical Engineering, Stanford University.
GregoryJ.Fluet目前是Ferring制药公司Rebiotix的首席运营官。自2016年11月以来,他一直在Rebiotix工作,担任合同和永久职位,包括从2017年4月起担任首席商务官,直到2018年4月被Ferring Pharmaceuticals收购。此前,他曾从事战略咨询实践,任职初创生命科学公司。他曾于2012年至2016年1月担任Urologix,Inc.(当时为一家上市公司)的首席执行官。他还曾于2014年8月至2015年5月担任其临时首席财务官,并于2008年至2012年担任其执行Vice President兼首席运营官。从2002年到2008年,他曾担任Sapient Capital Management公司(一个专注于梦百合的风险投资基金)的合伙人。他在Stanford University获得机械工程学士学位。
Gregory J. Fluet,serves as Chief Operating Officer for Ferring Microbiome Inc. (fka Rebiotix, Inc.), a Ferring Pharmaceuticals company focused on revolutionizing the treatment of debilitating diseases through microbiome-based research. Since 2016, he has worked at Rebiotix in both contract and permanent roles, including serving as Chief Business Officer from 2017 until the company's acquisition by Ferring Pharmaceuticals in 2018. Prior to this role at Rebiotix, Mr. Fluet served as Chief Executive Officer of Urologix, Inc., then a public company and developer of minimally invasive office-based Benign Prostatic Hyperplasia (BPH) therapies.BS, Mechanical Engineering, Stanford University.
Kathleen A. Tune

Kathleen A. Tune目前是Thomas, McNerney & Partners的合伙人。2000年到2003年期间,Tune女士曾受雇于Piper Jaffray Companies,并在此担任一名保健分析师,与医疗科技公司合作。在Piper的时候,她曾和包括医疗设备,医药攻击和诊断领域公司合作过。她曾受雇于Solvay, S.A.,并在现在属于Pfizer的一个部门工作,负责新产品的开发;还曾担任University of Minnesota高级科学人员。Tune女士目前在私营的Asante Solutions, Inc., AxioMed Spine Corporation以及 VertiFlex, Inc.三个机构的董事会任职,并且还是非盈利性的Mid-America Health Care Investors Network (MHIN)的总裁。她的教育背景包括University of Minnesota微生物学硕士学位和University of Minnesota商学院的工商管理硕士学位。


Kathleen A. Tune,currently serves as Managing Partner with Capita3, an early-stage venture capital fund focused on next generation healthcare startup founders, since January 2019. Ms. Tune was the CFO/COO for Marani Health, Inc., a leading development stage maternal and fetal health company, from 2020 through February 2024 and is a former Partner at Thomas, McNerney & Partners, where she led and managed an investment portfolio with a primary focus in healthcare technologies from 2003 to December 2019.BS, Biochemistry and Microbiology, Minnesota State University;MS, Veterinary Microbiology; University of Minnesota;MBA, Finance, University of Minnesota Carlson School of Management.
Kathleen A. Tune目前是Thomas, McNerney & Partners的合伙人。2000年到2003年期间,Tune女士曾受雇于Piper Jaffray Companies,并在此担任一名保健分析师,与医疗科技公司合作。在Piper的时候,她曾和包括医疗设备,医药攻击和诊断领域公司合作过。她曾受雇于Solvay, S.A.,并在现在属于Pfizer的一个部门工作,负责新产品的开发;还曾担任University of Minnesota高级科学人员。Tune女士目前在私营的Asante Solutions, Inc., AxioMed Spine Corporation以及 VertiFlex, Inc.三个机构的董事会任职,并且还是非盈利性的Mid-America Health Care Investors Network (MHIN)的总裁。她的教育背景包括University of Minnesota微生物学硕士学位和University of Minnesota商学院的工商管理硕士学位。
Kathleen A. Tune,currently serves as Managing Partner with Capita3, an early-stage venture capital fund focused on next generation healthcare startup founders, since January 2019. Ms. Tune was the CFO/COO for Marani Health, Inc., a leading development stage maternal and fetal health company, from 2020 through February 2024 and is a former Partner at Thomas, McNerney & Partners, where she led and managed an investment portfolio with a primary focus in healthcare technologies from 2003 to December 2019.BS, Biochemistry and Microbiology, Minnesota State University;MS, Veterinary Microbiology; University of Minnesota;MBA, Finance, University of Minnesota Carlson School of Management.
Kathleen S. Skarvan

Kathleen S. Skarvan由非管理董事向Electromed, Inc.的董事会推荐担任提名与治理委员会成员。自2012年12月起一直担任公司的首席执行官。从2011年11月到2012年10月担任OEM Fabricators的运营副总裁。在此之前,在Hutchinson Technology Incorporated担任各种角色,最后从2007年4月至2011年3月担任磁盘驱动器组件事业部的总裁,管理一家年收入超过3亿美元的上市公司事业部。2010年12月至2011年3月担任Hutchinson Technology Incorporated的高级副总裁。自2003年10月到2007年4月,担任磁盘驱动器组件事业部和营销部副总裁。


Kathleen S. Skarvan,is an experienced Board Director, accomplished CEO, and transformational strategic leader with financial and operational discipline in B2B and B2C markets. She currently serves as a Director on two public company boards C Electromed, Inc., where she was appointed Chair in 2023 following her tenure as President and CEO from 2012 to 2023, and Citizens Community Bancorp, Inc., where she serves as Chair of the Risk Oversight Committee and as a member of the Audit Committee. Earlier in her career, Ms. Skarvan spent over 30 years in high technology executive and general management roles, including Senior Vice President and President of Hutchinson Technology's Disk Drive Division, its largest business unit with $300 million in revenue and 3,500 employees. She is recognized for her transformational leadership style and hass a wealth of knowledge in technology products and services within highly regulated industries, delivering shareholder value through market strategy development and designing and overseeing comprehensive risk management systems. Ms. Skarvan has received numerous industry awards, including The Healthcare Technology Report's "Top 25 Women Leaders in Medical Devices of 2021" and the Minneapolis/St. Paul Business Journal's "Women in Business" honor in 2018. She holds a Bachelor's degree from St. Cloud State University and is a graduate of the University of Minnesota's Carlson School of Business Executive Program.
Kathleen S. Skarvan由非管理董事向Electromed, Inc.的董事会推荐担任提名与治理委员会成员。自2012年12月起一直担任公司的首席执行官。从2011年11月到2012年10月担任OEM Fabricators的运营副总裁。在此之前,在Hutchinson Technology Incorporated担任各种角色,最后从2007年4月至2011年3月担任磁盘驱动器组件事业部的总裁,管理一家年收入超过3亿美元的上市公司事业部。2010年12月至2011年3月担任Hutchinson Technology Incorporated的高级副总裁。自2003年10月到2007年4月,担任磁盘驱动器组件事业部和营销部副总裁。
Kathleen S. Skarvan,is an experienced Board Director, accomplished CEO, and transformational strategic leader with financial and operational discipline in B2B and B2C markets. She currently serves as a Director on two public company boards C Electromed, Inc., where she was appointed Chair in 2023 following her tenure as President and CEO from 2012 to 2023, and Citizens Community Bancorp, Inc., where she serves as Chair of the Risk Oversight Committee and as a member of the Audit Committee. Earlier in her career, Ms. Skarvan spent over 30 years in high technology executive and general management roles, including Senior Vice President and President of Hutchinson Technology's Disk Drive Division, its largest business unit with $300 million in revenue and 3,500 employees. She is recognized for her transformational leadership style and hass a wealth of knowledge in technology products and services within highly regulated industries, delivering shareholder value through market strategy development and designing and overseeing comprehensive risk management systems. Ms. Skarvan has received numerous industry awards, including The Healthcare Technology Report's "Top 25 Women Leaders in Medical Devices of 2021" and the Minneapolis/St. Paul Business Journal's "Women in Business" honor in 2018. She holds a Bachelor's degree from St. Cloud State University and is a graduate of the University of Minnesota's Carlson School of Business Executive Program.

高管简历

中英对照 |  中文 |  英文
James L. Cunniff

James L. Cunniff,2023年7月加入Electromed,担任公司总裁兼首席执行官。在加入Electromed之前,Cunniff先生最近于2017年至2022年5月担任Provista Inc.的总裁兼首席执行官。此前,他曾于2015年至2017年在Denver Solutions,LLC(d/b/a Leiters Health)担任总裁兼首席执行官,并于2012年至2014年在Acelity L.P. Inc.担任美洲区高级副总裁。Cunniff先生拥有伊利诺伊大学厄巴纳-香槟分校的广告和商业学士学位,并完成了哈佛商学院的高级管理课程。


James L. Cunniff,is a seasoned executive in the healthcare space with a direct knowledge of Electromed's business and operations as he currently serves as President and Chief Executive Officer of Electromed, Inc. Prior to joining Electromed in July of 2023, he served as President and Chief Executive Officer of Provista, Inc. (2017-2022) and of Denver Solutions, LLC (2015-2017).BA, Advertising and Business, University of Illinois Urbana-Champaign;Advanced Management Program, Harvard Business School.
James L. Cunniff,2023年7月加入Electromed,担任公司总裁兼首席执行官。在加入Electromed之前,Cunniff先生最近于2017年至2022年5月担任Provista Inc.的总裁兼首席执行官。此前,他曾于2015年至2017年在Denver Solutions,LLC(d/b/a Leiters Health)担任总裁兼首席执行官,并于2012年至2014年在Acelity L.P. Inc.担任美洲区高级副总裁。Cunniff先生拥有伊利诺伊大学厄巴纳-香槟分校的广告和商业学士学位,并完成了哈佛商学院的高级管理课程。
James L. Cunniff,is a seasoned executive in the healthcare space with a direct knowledge of Electromed's business and operations as he currently serves as President and Chief Executive Officer of Electromed, Inc. Prior to joining Electromed in July of 2023, he served as President and Chief Executive Officer of Provista, Inc. (2017-2022) and of Denver Solutions, LLC (2015-2017).BA, Advertising and Business, University of Illinois Urbana-Champaign;Advanced Management Program, Harvard Business School.
Bradley M. Nagel

布拉德利·M·内格尔,2022年11月加入Electromed,担任公司首席财务官、财务主管和秘书。在加入Electromed之前,Nagel先生最近于2018年6月至2022年11月在美敦力公司担任全球肺部健康和可视化部门首席财务官。此前,他曾于2016年至2018年6月在美敦力担任会计和销售业务高级经理,并于2015年至2016年担任会计经理。在加入美敦力之前,Nagel先生在塔吉特公司和TCF金融公司担任销售、运营和会计方面的各种职务。Nagel先生拥有加尔文大学商业与金融学士学位。


Bradley M. Nagel,joined Electromed in November 2022 as the Company's Chief Financial Officer, Treasurer and Secretary. Prior to joining Electromed, Mr. Nagel most recently served as Divisional Chief Financial Officer of Global Lung Health and Visualization at Medtronic plc from June 2018 to November 2022. Previously, he served at Medtronic as Sr. Manager, Accounting and Sales Operations from 2016 to June 2018 and Accounting Manager from 2015 to 2016. Before joining Medtronic, Mr. Nagel held various roles of increasing responsibility in sales, operations and accounting at Target Corporation and TCF Financial Corporation. Mr. Nagel holds a bachelor's degree in business & finance from Calvin University.
布拉德利·M·内格尔,2022年11月加入Electromed,担任公司首席财务官、财务主管和秘书。在加入Electromed之前,Nagel先生最近于2018年6月至2022年11月在美敦力公司担任全球肺部健康和可视化部门首席财务官。此前,他曾于2016年至2018年6月在美敦力担任会计和销售业务高级经理,并于2015年至2016年担任会计经理。在加入美敦力之前,Nagel先生在塔吉特公司和TCF金融公司担任销售、运营和会计方面的各种职务。Nagel先生拥有加尔文大学商业与金融学士学位。
Bradley M. Nagel,joined Electromed in November 2022 as the Company's Chief Financial Officer, Treasurer and Secretary. Prior to joining Electromed, Mr. Nagel most recently served as Divisional Chief Financial Officer of Global Lung Health and Visualization at Medtronic plc from June 2018 to November 2022. Previously, he served at Medtronic as Sr. Manager, Accounting and Sales Operations from 2016 to June 2018 and Accounting Manager from 2015 to 2016. Before joining Medtronic, Mr. Nagel held various roles of increasing responsibility in sales, operations and accounting at Target Corporation and TCF Financial Corporation. Mr. Nagel holds a bachelor's degree in business & finance from Calvin University.